What hyperbaric oxygen therapy actually is.
Hyperbaric Oxygen Therapy (HBOT) is the medical practice of breathing oxygen at pressures above sea level, inside a sealed chamber. At normal atmospheric pressure, hemoglobin in red blood cells carries almost all the oxygen in the body and plasma carries very little. Under pressure, oxygen dissolves directly into plasma, cerebrospinal fluid, and tissue fluid — raising tissue oxygen ten to fifteen times baseline.
Every documented effect of HBOT — from wound healing to stem cell release to telomere lengthening — traces back to that one physical change. It is the pressure combined with the oxygen that does the work. Pressure alone does not. Oxygen alone does not.
The Telo chamber implements the protocol at 1.5 ATA (equivalent to roughly 17 feet underwater), with 93% oxygen delivered through a mask rather than filling the chamber itself. This is the mask-delivery configuration used in soft-shell hyperbaric units. It keeps the chamber atmosphere at normal air composition, which is how electronics can operate inside without the fire precautions required by a pure-oxygen atmosphere.
What pressure actually does to arterial oxygen.
Hemoglobin is already 98% saturated at sea level. Pressure cannot add more oxygen there. What pressure can do is push oxygen directly into plasma, cerebrospinal fluid, and interstitial tissue. At 1.5 ATA with the 93% mask, plasma oxygen runs roughly 10× room-air baseline. That is the mechanism every downstream effect in the next section is built on.
What the research shows HBOT does.
The effects below have been measured in peer-reviewed human studies. They are outcomes — what is observed — not yet mechanisms. Each is paired with the sample size and the published source.
How this happens at the cellular level.
The outcomes above are driven by three mechanisms that repeat across the hyperbaric literature. All three are downstream of the same cause — elevated plasma oxygen under pressure — and they reinforce each other.
Stem cells released from bone marrow.
Elevated tissue oxygen triggers the release of CD34+ hematopoietic stem and progenitor cells from bone marrow into circulation, where they travel to areas of injury or oxidative stress. Thom's 2006 paper measured an eight-fold rise after a single session. This is the proposed driver of the regeneration and wound-healing effects documented across the hyperbaric literature.
Telomere lengthening and senescence clearing.
Telomeres are the protective caps at the end of chromosomes. They shorten with each cell division, and once they are too short the cell either stops dividing or becomes senescent. In Hadanny's 2020 protocol, 60 HBOT sessions produced 20–38% telomere lengthening in immune cells alongside a 10–37% drop in senescent cell counts — the first human intervention to move both biomarkers in the same study.
Mitochondrial biogenesis.
Mitochondria produce cellular energy. Sustained exposure to elevated oxygen combined with intermittent pressure stimulates mitochondrial biogenesis — the cell builds new mitochondria and improves the efficiency of existing ones. This is the same adaptive pathway triggered by endurance exercise, arrived at through a different stimulus.
Three decades of peer-reviewed research.
HBOT has an unusually long paper trail for a therapy still considered novel in longevity circles. FDA-approved for specific indications since 1985, it has been investigated at academic medical centers in the United States and Israel for regeneration, neurological recovery, cognitive decline, and chronic pain. Every study below links to the published source.
The UHMS and FDA begin recognizing HBOT as standard care for thirteen indications — carbon monoxide poisoning, decompression sickness, diabetic wounds, radiation injury, and more. HBOT enters mainstream medicine.
Thom et al. at the University of Pennsylvania measured an 8-fold increase in circulating CD34+ stem cells after a single HBOT session in healthy adults. Opened the door to HBOT as a longevity intervention, not just a wound-healing tool.
Two Tel Aviv University RCTs (Efrati & Boussi-Gross) showed measurable cognitive and neurological gains in patients one to five years past their injury. Demolished the "recovery window" assumption.
60 women with treatment-resistant fibromyalgia underwent 40 HBOT sessions. Pain scores dropped significantly; SPECT imaging showed normalized brain activity. Many were able to discontinue medication.
Hadanny et al. showed 60 HBOT sessions produced 20–38% telomere lengthening and a 10–37% reduction in senescent cells in healthy aging adults. The first human intervention to reverse two primary aging biomarkers simultaneously — the paper the longevity field pointed at all year.
Shapira et al. demonstrated HBOT reduces amyloid-β plaques, improves cerebral blood flow, and produces measurable cognitive gains in aging patients with memory decline. Addresses Alzheimer's pathology upstream.
Current trials investigate HBOT in long COVID, depression, post-surgical recovery, and healthy aging. The protocol is no longer a debate — the open question is how far it generalizes.
The 1.5 ATA decision, and what it trades off.
Pressure is the lever that makes hyperbaric work, and different pressures are suited to different use cases. The Telo chamber operates at 1.5 ATA because that level is where three constraints intersect: it produces the documented physiological effects, it remains comfortable enough for daily use, and it can be safely maintained in a soft-shell unit at home without medical supervision. Here is the trade-off behind each of those constraints.
Ear and sinus equalization.
At 1.5 ATA, ear and sinus pressure differentials are mild and most people equalize during the initial pressurization without discomfort. Above this level, equalization becomes harder and clinical protocols are typically run under supervision. 1.5 ATA is the ceiling for routine unsupervised home use.
Built for the 40 to 60 session protocol.
Every documented longevity outcome comes from repeated use. Forty to sixty sessions of 60 to 90 minutes, five days a week, across two or three months. That cadence is where the effect lives. A home chamber at 1.5 ATA is the format that actually makes it realistic. The session happens whenever fits your day, and inside the chamber you can nap, read, work, or take a call.
Physiological effect per session.
At 1.5 ATA with 93% oxygen through the mask, arterial oxygen partial pressure rises roughly 4–5x baseline. This is enough to drive the cellular mechanisms documented in Section 03. For chronic, repeated use the dose-response curve flattens above this range, which is why longevity-oriented protocols tend to cluster here rather than at clinical peaks.
Where 1.5 ATA sits on the clinical-to-home continuum.
1.5 ATA / Telo
Equivalent to roughly 17 feet underwater. At this pressure paired with 93% oxygen via mask, arterial oxygen partial pressure rises about 4–5x baseline — enough to drive the cellular mechanisms documented in Section 03. It is the ceiling pressure that a soft-shell chamber can safely maintain for daily unsupervised use, and the level where the dose-response curve for chronic protocols begins to plateau.
Daily home protocolWhat HBOT doesn't do, and who it isn't for.
The longevity space tends to overstate what hyperbaric oxygen can deliver and understate its boundaries. This section is the part of the page that sells least. It exists so a reader can decide for themselves whether the protocol fits the problem they're trying to solve.
People who should not use HBOT without medical clearance.
HBOT is not safe for everyone. Documented contraindications include:
- Untreated pneumothorax (collapsed lung). The single absolute contraindication.
- Active chemotherapy with certain agents (bleomycin, cisplatin, doxorubicin). Oxygen interaction with these drugs can be dangerous.
- Uncontrolled seizure disorders, severe COPD with CO₂ retention, or recent ear/sinus surgery.
- Upper respiratory infection or congested sinuses at the time of a session — pressurization can cause ear or sinus barotrauma.
Anyone with a chronic condition should clear HBOT use with their physician before starting a home protocol.
Cases where HBOT is likely not worth the investment.
- Anyone who cannot equalize ear pressure reliably. If airline flights or scuba cause persistent ear pain, a daily hyperbaric protocol will not work.
- People seeking immediate effect. Single-session benefits are subtle; the documented outcomes come from sustained cadence over weeks.
- Anyone unable to commit to the protocol. Running two sessions a week does not replicate the effect sizes in the longevity literature. Consistency is the active ingredient.
Go deeper than this page.
Primary literature, review articles, and independent conversations on hyperbaric oxygen therapy. None of these are affiliated with Telo.
If you've read this far and the protocol makes sense for what you're trying to do, the Telo Protocol chamber is a 1.5 ATA implementation built for daily home use.
Back to the Telo Protocol chamber →